biocon q3 earnings: Biocon Q3 Results: PAT at Rs 660 crore vs Rs 42-crore loss a year ago
The company said the revenue growth was supported by income from the divesture of two non-core business assets of Biocon Biologics' branded formulations India business amounting to Rs 350 crore and a gain of Rs 456 crore from Biocons stake dilution in Bicara Therapeutics.
Source: indiatimes.com